Economic evaluation of new targeted therapies for the first-line treatment of patients with metastatic renal cell carcinoma

BJU International

Volumn 108, Issue 5, 2011, Pages 665-672

  Benedict, Ágnes ^a   Figlin, Robert A ^b   Sandström, Per ^e   Harmenberg, Ulrika ^e   Ullén, Anders ^e   Charbonneau, Claudie ^c,d   Sandin, Rickard ^f   Remák, Edit ^a   Hariharan, Subramanian ^d   Négrier, Sylvie ^g  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c Global Health Outcomes   (United States)

^d Pfizer Ltd   (United States)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^f PFIZER INC   (United States)

^g CENTRE LÉON BÉRARD   (France)

Author keywords

cost effectiveness; renal cell carcinoma; sunitinib; targeted therapy

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; PLACEBO; SORAFENIB; SUNITINIB;

ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; ECONOMIC EVALUATION; HEALTH ECONOMICS; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; METASTASIS; MOLECULARLY TARGETED THERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; SWEDEN; UNITED STATES; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, RENAL CELL; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; DRUG COSTS; FEMALE; HUMANS; INDOLES; INTERFERON-ALPHA; KIDNEY NEOPLASMS; MALE; MARKOV CHAINS; MOLECULAR TARGETED THERAPY; PYRIDINES; PYRROLES; QUALITY-ADJUSTED LIFE YEARS; SWEDEN; UNITED STATES;

EID: 80051746090     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2010.09957.x     Document Type: Article

References (36)

1. National Institute for Clinical Excellence (NICE). Technology appraisal guidance 169: sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma. Available at:. Accessed March 2010
2. The Swedish Pharmaceutical Benefits Board (LFN). Guidelines for companies. Available at:. Accessed March 2010
3. Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press, 1996
4. Drummond M, McGuire A, eds. Economic Evaluation in Health Care: Merging Theory with Practice. Oxford: Oxford University Press, 2001
5. Pharmaceutical Benefits Board. General guidelines for economic evaluation from the Pharmaceutical Benefits Board. Available at:. Accessed March 2010
6. VÃ¥rdprogramgrappen, Nationellt VÃ¥rdprogram Njurcancer, 2008. Swedish national guidelines for treatment of renal cancer. Available at:. Accessed March 2010
7. Motzer RJ, Figlin RA, Hutson TE, et al,. Sunitinib versus interferon-alfa (IFN-α) as first-line treatment of metastatic renal cell carcinoma (mRCC): updated results and analysis of prognostic factors. Oral presentation at the American Society of Clinical Oncology Annual Meeting, Chicago, USA, 1-5 June 2007 (Abstract 5024)
8. Figlin RA, Hutson TE, Tomczak P, et al,. Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC). Oral presentation at the 44th Annual Meeting of the American Society of Clinical Oncology, Chicago, Illinois, 30 May to 3 June 2008 (Abstract 5028)
9. Negrier S, Figlin R, Hutson TE, et al,. Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC). Poster presentation at the 33rd European Society for Medical Oncology Congress, Stockholm, Sweden, 12-16 September 2008 (Abstract 588PD)
10. Szczylik C, Demkow T, Staehler M, et al,. Randomized phase II trial of first line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: final results. Oral presentation at the 43rd Annual Meeting of the American Society of Clinical Oncology, Chicago, Illinois, 1-5 June 2007 (Abstract 5025)
11. Bukowski R, Eisen T, Szczylik C, et al,. Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: survival and biomarker analysis. Oral presentation at the 43th Annual Meeting of the American Society of Clinical Oncology, Chicago, Illinois, 1-3 June 2007 (Abstract 5023)
12. Escudier B, Pluzanska A, Koralewski P, et al,. AVOREN Trial investigators. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007; 370: 2103-11 (Pubitemid 350296300)
13. Escudier BJ, Bellmunt J, Negrier S, et al,. Final results of the phase III, randomized, double-blind AVOREN trial of first-line bevacizumab (BEV) + interferon-a2a (IFN) in metastatic renal cell carcinoma (mRCC). Oral presentation at the 45th Annual Meeting of the American Society of Clinical Oncology, Orlando, FL, 29 May-2 June 2009 (abstract 5020)
14. Remák E, Charbonneau C, Négrier S, Kim ST, Motzer RJ,. Economic evaluation of sunitinib malate for the first-line treatment of metastatic renal cell carcinoma. J Clin Oncol 2008; 26: 3995-4000
15. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-24 (Pubitemid 46089672)
16. Motzer RJ, Michaelson MD, Redman BG, et al,. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 16-24 (Pubitemid 46630489)
17. Centers for Medicare and Medicaid Services. 2006 ASP drug pricing files. Available at:. Accessed September 2009
18. Fleming T,. Red Book®: Pharmacy's Fundamental Reference™. Montvale: Thomson Healthcare, 2007
19. Agency for Healthcare Research and Quality (AHRQ). Healthcare Cost and Utilisation Project (HCUP) Nationwide Inpatient Sample (NIS). Available at:. Accessed November 2008
20. American Medical Association (AMA). AMA Current Procedural Terminology (CPT) codes/Value Search. Available at:. Accessed November 2008
21. Västra Götaland region, Sahlgrenska University Hospital inter-county prices/Utomlänspriser 2008. Available at:. Accessed March 2009
22. Karolinska University Hospital price list for inter-county care 2008. Available at:. Accessed March 2009
23. Southern Regional Health Care Committee, Regional prices and fees of the southern health care region 2009. Available at. Accessed March 2009
24. Västra Götaland region, Sahlgrenska University Hospital inter-county prices 2009. Available at:. Accessed March 2009
25. Samverkansnämnden, Uppsala-Örebroregionen, County Council of Uppsala. Uppsala Academic Hospital regional price list 2008. Available at:. Accessed March 2009
26. OANDA. Average exchange rates. Available at:. Accessed April 2009
27. Sveriges Riksbank. Exchange rates. Available at:. Accessed April 2009
28. Briggs A, Claxton K, Sculpher M,. Decision Modelling for Health Economic Evaluation. Oxford: Oxford University Press, 2006
29. Mills EJ, Rachlis B, O'Regan C, Thabane L, Perri D,. Metastatic renal cell cancer treatments: an indirect comparison meta-analysis. BMC Cancer 2009; 9: 34
30. Rini BI, Halabi S, Rosenberg JE, et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008; 26: 5422-8
31. Lothgren M, Zethraeus N,. Definition, interpretation and calculation of cost-effectiveness acceptability curves. Health Econ 2000; 9: 623-30
32. Thompson Coon J, Hoyle M, Green C, et al,. Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation. Health Technol Assess 2010; 14: 1-184, iii- iv
33. National Institute for Clinical Excellence (NICE). Technology appraisal guidance 178: bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma. Available at:. Accessed March 2010
34. Diaz S, Calvo Aller E, Maroto P, Puente J, Lõpez-Brea M, Castellano D,. Cost-effectiveness and cost-utility analysis of sunitinib vs sorafenib and bevacizumab + interferon-alfa as first-line treatment for metastatic renal cell carcinoma in Spain. Poster presentation at the 33rd European Society of Medical Oncology Congress, Stockholm, Sweden, 12-16 September 2008 (Abstract 724P)
35. Mickisch G, Gore M, Escudier B, Procopio G, Walzer S, Nuijten M,. Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib. Br J Cancer 2010; 102: 80-6
36. Benedict Á, Charbonneau C, Hidi J, Kim ST, Négrier S,. Economic evaluation of sunitinib, sorafenib, bevacizumab/interferon-alfa or temsirolimus in 1st-line treatment of metastatic renal cell carcinoma (mRCC): an indirect comparison. Poster presentation at the 44th Annual Meeting of the American Society of Clinical Oncology, Chicago, Illinois, 30 May to 3 June 2008 (Abstract 5048)